Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/30096
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTishova, Y-
dc.contributor.authorKalinchenko, S-
dc.contributor.authorMskhalaya, G-
dc.contributor.authorHackett, G-
dc.contributor.authorLivingston, M-
dc.contributor.authorKönig, C-
dc.contributor.authorStrange, R-
dc.contributor.authorZitzmann, M-
dc.contributor.authorMann, A-
dc.contributor.authorMaarouf, A-
dc.contributor.authorRamachandran, S-
dc.date.accessioned2024-11-11T16:29:47Z-
dc.date.available2024-11-11T16:29:47Z-
dc.date.issued2024-03-03-
dc.identifierORCiD: Carola König https://orcid.org/0000-0002-9289-3154-
dc.identifier.citationTishova, Y. et al. (2024) 'Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase', Diabetes, Obesity and Metabolism, 26 (6), pp. 2147 - 2157. doi: 10.1111/dom.15520.en_US
dc.identifier.issn1462-8902-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/30096-
dc.descriptionData Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.en_US
dc.description.abstractAims: To describe changes in homeostasis model assessment of insulin resistance index (HOMA-IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS). Materials and Methods: A randomized, placebo-controlled, double-blind randomized controlled trial (RCT) comprising 184 men with MetS and hypogonadism (testosterone undecanoate [TU]: 113 men, placebo: 71 men) was conducted. This was followed by an open-label phase in which all men were given TU. We focused on men who were not receiving antiglycaemic agents (TU: 81 men; placebo: 54 men) as these could affect HOMA-IR. Inter-group comparison of HOMA-IR was restricted to the RCT (30 weeks), whilst intra-group comparison was carried out on men provided TU during the RCT and open-label phases (study cohort) and men given placebo during the RCT and then switched to TU during the open-label phase (confirmatory cohort). Regression analysis was performed to identify factors associated with change in HOMA-IR (∆HOMA-IR). Results: The median HOMA-IR was significantly reduced at almost every time point (after 18 weeks) compared to baseline in men receiving TU in both the study and confirmatory cohorts. There was a significant decrease in median values of fasting glucose (30 weeks: −2.1%; 138 weeks: −4.9%) and insulin (30 weeks: −10.5%; 138 weeks: −35.5%) after TU treatment. Placebo was not associated with significant ∆HOMA-IR. The only consistent predictor of HOMA-IR decrease following TU treatment was baseline HOMA-IR (r2 ≥ 0.64). Conclusions: Baseline HOMA-IR predicted ΔHOMA-IR, with a greater percentage change in insulin than in fasting glucose. In men with MetS/type 2 diabetes (T2DM) not on antiglycaemic therapy, improvements in HOMA-IR may be greater than suggested by change in fasting glucose. Our results suggest that hypogonadism screening be included in the management of men with MetS/T2DM.en_US
dc.description.sponsorshipNorth Staffordshire Medical Institute. Grant Number: PID-200078en_US
dc.format.extent2147 - 2157-
dc.format.mediumPrint-Electronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/-
dc.subjectadult-onset hypogonadismen_US
dc.subjectinsulin resistanceen_US
dc.subjectmetabolic syndromeen_US
dc.subjecttestosterone therapyen_US
dc.subjectwaist circumferenceen_US
dc.titleTestosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phaseen_US
dc.typeArticleen_US
dc.date.dateAccepted2024-02-11-
dc.identifier.doihttps://doi.org/10.1111/dom.15520-
dc.relation.isPartOfDiabetes, Obesity and Metabolism-
pubs.issue6-
pubs.publication-statusPublished-
pubs.volume26-
dc.identifier.eissn1463-1326-
dc.rights.licensehttps://creativecommons.org/licenses/by-nc/4.0/legalcode.en-
dc.rights.holderThe Authors-
Appears in Collections:Dept of Mechanical and Aerospace Engineering Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.1.13 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons